Yonsei Med J.  2007 Feb;48(1):69-77. 10.3349/ymj.2007.48.1.69.

The Prevalence of Human Papillomavirus Infection in Korean Non-Small Cell Lung Cancer Patients

• Park MS
• Chang YS
• Shin JH
• Kim DJ
• Chung KY
• Shin DH
• Moon JW
• Kang SM
• Hahn CH
• Kim YS
• Chang J
• Kim SK
• Kim SK

• KMID: 1093526
• DOI: http://doi.org/10.3349/ymj.2007.48.1.69

Abstract

Human papillomavirus (HPV) infection is a co-carcinogen of lung cancer and contributes to its pathogenesis. To evaluate the prevalence of HPV infection, polymerase chain reaction (PCR) was employed to detect HPV 16, 18, and 33 DNA in tumor tissues of 112 patients with non-small cell lung cancer (NSCLC) who underwent curative surgery from Jan. 1995 to Dec. 1998 at Severance Hospital, Seoul, Korea. The patients consisted of 90 men and 22 women. Nineteen patients were under 50 years old (17%), and 92 patients (82%) were smokers. Fifty-three patients had adenocarcinomas, while 59 patients had non-adenocarcinomas. Early stage (I and II) cancer was found in 64 patients (57.1%) and advanced stage (III and IV) found in 48 (42.9%). The prevalence of HPV 16, 18, and 33 were 12 (10.7%), 11 (9.8%), and 37 (33.0%), respectively. Smoking status, sex, and histologic type were not statistically different in the presence of HPV DNA. The presence of HPV 16 was more common in younger patients and HPV 18 was more common in advanced stage patients. This study showed that the prevalence rate of HPV 16 and 18 infections in NSCLC tissue was low, suggesting HPV 16 and 18 infections played a limited role in lung carcinogenesis of Koreans. However, the higher prevalence of HPV 33 infections in Korean lung cancer patients compared to other Asian and Western countries may be important and warrants further investigation.

Keyword

Non-small cell lung carcinoma; carcinogenesis; human papillomavirus; polymerase chain reaction

Figure

• 

  Fig. 1 Representative results of polymerase chain reaction (PCR) with HPV-type specific primers for negative and positive HPV DNA detection in tumor tissue. SM, size marker; Lane 1: negative HPV DNA; Lane 2: positive HPV DNA; Lane 3: positivecontrol; Lane 4: negative control.

• 

  Fig. 2 Kaplan-Meier survival curves of HPV 16, 18, and 33 infections in patients with non-small cell lung cancer. No significant difference in survival times was observed (log rank test, p > 0.05).

Reference

1. Korea Central Cancer Registry, Ministry of Health and Welfare Republic of Korea. Annual Report of the Korea Central Cancer Registry. 2002.

2. Wood ME, Kelly K, Mullineaux LG, Bunn PA Jr. The inherited nature of lung cancer: a pilot study. Lung Cancer. 2000. 30:135–144.

3. zur Hausen H. Papillomaviruses in human cancers. Proc Assoc Am Physicians. 1999. 111:581–587.

4. Werness BA, Levine AJ, Howley PM. Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science. 1990. 248:76–79.

5. Scheffner M, Werness BA, Huibregtse JM, Levine AJ, Howley PM. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell. 1990. 63:1129–1136.

6. Storey A, Thomas M, Kalita A, Harwood C, Gardiol D, Mantovani F, et al. Role of a p53 polymorphism in the development of human papillomavirus-associated cancer. Nature. 1998. 393:229–234.

7. Syrjanen KJ. HPV infections and lung cancer. J Clin Pathol. 2002. 55:885–891.

8. Cheng YW, Chiou HL, Sheu GT, Hsieh LL, Chen JT, Chen CY, et al. The association of human papillomavirus 16/18 infection with lung cancer among non-smoking Taiwanese women. Cancer Res. 2001. 61:2799–2803.

9. Chiou HL, Wu MF, Liaw YC, Cheng YW, Wong RH, Chen CY, et al. The presence of human papillomavirus type 16/18 DNA in blood circulation may act as a risk marker of lung cancer in Taiwan. Cancer. 2003. 97:1558–1563.

10. Tsuhako K, Nakazato I, Hirayasu T, Sunakawa H, Iwamasa T. Human papillomavirus DNA in adenosquamous carcinoma of the lung. J Clin Pathol. 1998. 51:741–749.

11. Soini Y, Nuorva K, Kamel D, Pollanen R, Vahakangas K, Lehto VP, et al. Presence of human papillomavirus DNA and abnormal p53 protein accumulation in lung carcinoma. Thorax. 1996. 51:887–893.

12. Hirayasu T, Iwamasa T, Kamada Y, Koyanagi Y, Usuda H, Genka K. Human papillomavirus DNA in squamous cell carcinoma of the lung. J Clin Pathol. 1996. 49:810–817.

13. Hennig EM, Suo Z, Karlsen F, Holm R, Thoresen S, Nesland JM. HPV positive bronchopulmonary carcinomas in women with previous high-grade cervical intraepithelial neoplasia (CIN III). Acta Oncol. 1999. 38:639–647.

14. Shimada M, Fukushima M, Mukai H, Kato I, Nishikawa A, Fujinaga K. Amplification and specific detection of transforming gene region of human papillomavirus 16, 18 and 33 in cervical carcinoma by means of the polymerase chain reaction. Jpn J Cancer Res. 1990. 81:1–5.

15. Shamanin V, Delius H, de Villiers EM. Development of a broad spectrum PCR assay for papillomaviruses and its application in screening lung cancer biopsies. J Gen Virol. 1994. 75:1149–1156.

16. Szabo I, Sepp R, Nakamoto K, Maeda M, Sakamoto H, Uda H. Human papillomavirus not found in squamous and large cell lung carcinomas by polymerase chain reaction. Cancer. 1994. 73:2740–2744.

17. Welt A, Hummel M, Niedobitek G, Stein H. Human papillomavirus infection is not associated with bronchial carcinoma: evaluation by in situ hybridization and the polymerase chain reaction. J Pathol. 1997. 181:276–280.

18. Joo WD, Kim SH, Kim DY, Suh DS, Kim JH, Kim YM, et al. Prevalence of human papillomavirus infection in Korean women: risks of abnormal pap smear and cervical neoplasia. Korean Soc Gynecol Oncol Colposcopy. 2004. 15:309–316.

19. Skegg DC, Corwin PA, Paul C, Doll R. Importance of the male factor in cancer of the cervix. Lancet. 1982. 2:581–583.

20. Okinawa Prefectural Government. Annual statistical report of health and environment 1986-1995. 1995. Okinawa: Okinawa Prefectural Government.

21. Miyagi J, Tsuhako K, Kinjo T, Iwamasa T, Hirayasu T. Recent striking changes in histological differentiation and rate of human papillomavirus infection in squamous cell carcinoma of the lung in Okinawa, a subtropical island in southern Japan. J Clin Pathol. 2000. 53:676–684.

22. Miyagi J, Kinjo T, Tsuhako K, Higa M, Iwamasa T, Kamada Y, et al. Extremely high Langerhans cell infiltration contributes to the favourable prognosis of HPV-infected squamous cell carcinoma and adenocarcinoma of the lung. Histopathology. 2001. 38:355–367.

23. Clavel CE, Nawrocki B, Bosseaux B, Poitevin G, Putaud IC, Mangeonjean CC, et al. Detection of human papillomavirus DNA in bronchopulmonary carcinomas by hybrid capture II: a study of 185 tumors. Cancer. 2000. 88:1347–1352.

24. Hiroshima K, Toyozaki T, Iyoda A, Ohwada H, Kado S, Shirasawa H, et al. Ultrastructural study of intranuclear inclusion bodies of pulmonary adenocarcinoma. Ultrastruct Pathol. 1999. 23:383–389.

25. Yousem SA, Ohori NP, Sonmez-Alpan E. Occurrence of human papillomavirus DNA in primary lung neoplasms. Cancer. 1992. 69:693–697.

26. Bohlmeyer T, Le TN, Shroyer AL, Markham N, Shroyer KR. Detection of human papillomavirus in squamous cell carcinomas of the lung by polymerase chain reaction. Am J Respir Cell Mol Biol. 1998. 18:265–269.

27. Gorgoulis VG, Zacharatos P, Kotsinas A, Kyroudi A, Rassidakis AN, Ikonomopoulos JA, et al. Human papilloma virus (HPV) is possibly involved in laryngeal but not in lung carcinogenesis. Hum Pathol. 1999. 30:274–283.

28. Chen YC, Chen JH, Richard K, Chen PY, Christiani DC. Lung adenocarcinoma and human papillomavirus infection. Cancer. 2004. 101:1428–1436.

29. Gillison ML, Shah KV. Chapter 9: Role of mucosal human papillomavirus in nongenital cancers. J Natl Cancer Inst Monogr. 2003. 31:57–65.

30. Tseng CJ, Pao CC, Lin JD, Soong YK, Hong JH, Hsueh S. Detection of human papillomavirus types 16 and 18 mRNA in peripheral blood of advanced cervical cancer patients and its association with prognosis. J Clin Oncol. 1999. 17:1391–1396.

31. Capone RB, Pai SI, Koch WM, Gillison ML, Danish HN, Westra WH, et al. Detection and quantitation of human papillomavirus (HPV) DNA in the sera of patients with HPV-associated head and neck squamous cell carcinoma. Clin Cancer Res. 2000. 6:4171–4175.

32. Shyu JS, Chen CJ, Chiu CC, Huang SC, Harn HJ. Correlation of human papillomavirus 16 and 18 with cervical neoplasia in histological typing and clinical stage in Taiwan: an in-situ polymerase chain reaction approach. J Surg Oncol. 2001. 78:101–109.

33. Kurman RJ, Schiffman MH, Lancaster WD, Reid R, Jenson AB, Temple GF, et al. Analysis of individual human papillomavirus types in cervical neoplasia: a possible role for type 18 in rapid progression. Am J Obstet Gynecol. 1988. 159:293–296.

34. Walker J, Bloss JD, Liao SY, Berman M, Bergen S, Wilczynski SP, et al. Human papillomavirus genotype as a prognostic indicator in carcinoma of the uterine cervix. Obstet Gynecol. 1989. 74:781–785.

35. Barbosa MS, Edmonds C, Fisher C, Schiller JT, Lowy DR, Vousden KH, et al. The region of the HPV E7 oncoprotein homologous to adenovirus E1a and Sv40 large T antigen contains separate domains for Rb binding and casein kinase II phosphorylation. EMBO J. 1990. 9:153–160.

36. Dallenbach-Hellweg G, Lang G. Immunohistochemical studies on uterine tumors. Invasive squamous cell carcinomas of the cervix and their precursors. Pathol Res Pract. 1991. 187:36–43.

37. Kim SW, Yang JS. Human papillomavirus type 16 E5 protein as a therapeutic target. Yonsei Med J. 2006. 47:1–14.

38. Nuorva K, Soini Y, Kamel D, Pollanen R, Bloigu R, Vahakangas K, et al. p53 protein accumulation and the presence of human papillomavirus DNA in bronchiolo-alveolar carcinoma correlate with poor prognosis. Int J Cancer. 1995. 64:424–429.